Literature DB >> 7149108

Dengue-2 vaccine: oral infection, transmission, and lack of evidence for reversion in the mosquito, Aedes aegypti.

B R Miller, B J Beaty, T H Aitken, K H Eckels, P K Russell.   

Abstract

The dengue-2 vaccine virus (S-1), and its parent virus (PR-159), were compared for their ability to infect orally, to replicate in, and subsequently to be transmitted by Aedes aegypti mosquitoes. The vaccine virus was markedly less efficient in its ability to infect mosquitoes orally. After ingesting infectious bloodmeals containing 3, 7 to 8.2 log10MID50/ml of the respective viruses, 56% (220/396) of the mosquitoes became orally infected with the parent virus contrasted with 16% (66/397) for the vaccine virus. None of the 16 infected mosquitoes transmitted the vaccine virus, while 14% (3/22) of the mosquitoes transmitted the parent virus. The vaccine virus remained temperature-sensitive (restrictive temperature 39 degrees C) after orally infecting and replicating in Ae. aegypti mosquitoes.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7149108     DOI: 10.4269/ajtmh.1982.31.1232

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  9 in total

1.  Dengue 2 PDK-53 virus as a chimeric carrier for tetravalent dengue vaccine development.

Authors:  Claire Y-H Huang; Siritorn Butrapet; Kiyotaka R Tsuchiya; Natth Bhamarapravati; Duane J Gubler; Richard M Kinney
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

2.  Attenuation markers of a candidate dengue type 2 vaccine virus, strain 16681 (PDK-53), are defined by mutations in the 5' noncoding region and nonstructural proteins 1 and 3.

Authors:  S Butrapet; C Y Huang; D J Pierro; N Bhamarapravati; D J Gubler; R M Kinney
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

3.  Chimeric dengue type 2 (vaccine strain PDK-53)/dengue type 1 virus as a potential candidate dengue type 1 virus vaccine.

Authors:  C Y Huang; S Butrapet; D J Pierro; G J Chang; A R Hunt; N Bhamarapravati; D J Gubler; R M Kinney
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

4.  Reduced infection in mosquitoes exposed to blood meals containing previously frozen flaviviruses.

Authors:  Stephanie L Richards; Kendra Pesko; Barry W Alto; Christopher N Mores
Journal:  Virus Res       Date:  2007-08-07       Impact factor: 3.303

5.  Limited Transmission Potential of Takeda's Tetravalent Dengue Vaccine Candidate by Aedes albopictus.

Authors:  Elizabeth A Dietrich; Yee Tsuey Ong; Janae L Stovall; Hansi Dean; Claire Y-H Huang
Journal:  Am J Trop Med Hyg       Date:  2017-08-18       Impact factor: 2.345

6.  Titration of dengue viruses by immunofluorescence in microtiter plates.

Authors:  R J Schoepp; B J Beaty
Journal:  J Clin Microbiol       Date:  1984-11       Impact factor: 5.948

Review 7.  Understanding the dengue viruses and progress towards their control.

Authors:  Rosmari Rodriguez-Roche; Ernest A Gould
Journal:  Biomed Res Int       Date:  2013-07-09       Impact factor: 3.411

8.  Vector Competence of American Mosquitoes for Three Strains of Zika Virus.

Authors:  James Weger-Lucarelli; Claudia Rückert; Nunya Chotiwan; Chilinh Nguyen; Selene M Garcia Luna; Joseph R Fauver; Brian D Foy; Rushika Perera; William C Black; Rebekah C Kading; Gregory D Ebel
Journal:  PLoS Negl Trop Dis       Date:  2016-10-26

9.  Dengue Virus Infection of Aedes aegypti Requires a Putative Cysteine Rich Venom Protein.

Authors:  Berlin Londono-Renteria; Andrea Troupin; Michael J Conway; Diana Vesely; Michael Ledizet; Christopher M Roundy; Erin Cloherty; Samuel Jameson; Dana Vanlandingham; Stephen Higgs; Erol Fikrig; Tonya M Colpitts
Journal:  PLoS Pathog       Date:  2015-10-22       Impact factor: 6.823

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.